America's Epidemic of STDs May Finally Be Slowing
By Dennis Thompson HealthDay Reporter
TUESDAY, Nov. 11, 2024 -- The epidemic of sexually transmitted infections (STIs) in the United States appears to be cooling off after more than two decades, a new Centers for Disease Control and Prevention (CDC) study says.
Gonorrhea cases dropped for a second year in 2023, declining 7% and falling below pre-pandemic levels, researchers say.
And syphilis cases increased by 1%, after years of double-digit growth.
“I see a glimmer of hope amidst millions of STIs,” Dr. Jonathan Mermin, director of the CDC’s National Center for HIV, Viral Hepatitis, STD, and TB Prevention, said in a news release.
“After nearly two decades of STI increases, the tide is turning,” he continued. “We must make the most of this moment — let’s further this momentum with creative innovation and further investment in STI prevention.”
However, STIs remain widespread in the United States, researchers found.
Compared to 20 years ago, more than a million more STIs were reported annually in 2023, the study shows.
Last year, nearly 4,000 U.S. babies were born with syphilis. There was a 3% increase in newborn syphilis cases, which is an improvement given the 30% annual increases seen in prior years, experts said.
It also appears that increases in newborn syphilis appear to be slowing in some parts of the U.S., researchers said.
Cases of the most infectious stages of syphilis, primary and secondary syphilis, fell 10% in 2023, the first substantial decline in more than two decades, researchers said.
Cases of syphilis also dropped 13% among gay and bisexual men, the first decrease since the mid-2000s when the CDC began tracking trends among them.
CDC experts said the decreases follow important developments and innovations in STI prevention, such as:
New guidelines for using doxycycline after exposure to bacterial STIs, to prevent infection.
Newly approved at-home tests for syphilis, gonorrhea and chlamydia.
A nationally coordinated response to the U.S. syphilis epidemic spearheaded by a federal task force.
However, the CDC said efforts to develop new prevention, testing and treatment solutions for different groups in the U.S. need to continue, along with increasing local access to STI testing and services.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-11-13 06:00
Read more
- Study Characterizes Pediatric Patients Self-Presenting With Major Trauma
- Obesity-Linked Heart Deaths Nearly Tripled in U.S. Over Past Two Decades
- Avadel Pharmaceuticals Announces FDA Approval of Lumryz (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy
- Nipocalimab Demonstrates Sustained Disease Control in Adolescents Living with Generalized Myasthenia Gravis in Phase 2/3 study
- 2008 to 2022 Saw Rise in Industry-Sponsored Adult Cancer Clinical Trials
- Diabetes & Kidney Trouble Can Bring Heart Disease Decades Earlier
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions